Piper Sandler Maintains Overweight on Tandem Diabetes Care, Lowers Price Target to $25
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) but lowers the price target from $40 to $25.

November 02, 2023 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler has maintained an Overweight rating on Tandem Diabetes Care but lowered the price target from $40 to $25.
The lowering of the price target by Piper Sandler from $40 to $25 indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that the analyst still sees potential in the company's stock, which could mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100